Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Delaying Inclusion Of Oral-Only ESRD Drugs In Bundled Payment Gives Short-Term Reprieve To Genzyme, Amgen

Executive Summary

Although manufacturers and other stakeholders were unable to convince CMS to change its stance on including oral-only drugs to treat end-stage renal disease in a new prospective payment system, the agency's decision to delay that step for three years is being viewed as a somewhat positive result for Amgen and Genzyme in the short term

You may also be interested in...



Patient-Reported Outcomes Are Key To Understanding Success of Bundled Payments – NPC’s Dubois

Experience with the end-stage renal disease prospective payment system reveals a valuable lesson – that patient-related quality metrics are needed to fully assess the impact the system has on the patient, something that will be valuable when bundling is considered for treatments where drug costs are significant.

Bill To Overturn Delay In Bundling Oral-Only Drugs For ESRD Introduced

Rep. Peter Welch introduces a bill that would overturn a provision in the American Taxpayer Relief Act delaying the bundling of oral-only drugs for ESRD treatment, such as Amgen’s Sensipar, until 2016.

GAO Tracks Decline In ESA Use Following Regulatory Changes

A Government Accountability Office report finds that use of erthryopoiesis-stimulating agents in dialysis decreased 31% from 2007 to the end of 2011 after Medicare’s bundled dialysis payment was changed to include drugs and FDA revised dosing recommendations.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052474

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel